GICR (Global Initiative for Cancer Registry Development) is a unified strategy for international partners to share knowledge and facilitate research to inform cancer control.
Overall survival was significantly improved by the administration of first-line pertuzumab, trastuzumab and docetaxel in the CLEOPATRA (Clinical Evaluation of Pertuzumab and Trastuzumab) study.
The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) has updated Appendix A in the NIOSH Alert: Preventing Occupational Exposure to Antineoplastic and Other Hazardous Drugs in Health Care Settings.
